2. Academic Validation
  3. Discovery of an Orally Efficacious Positive Allosteric Modulator of the Glucagon-like Peptide-1 Receptor

Discovery of an Orally Efficacious Positive Allosteric Modulator of the Glucagon-like Peptide-1 Receptor

  • J Med Chem. 2021 Mar 25;64(6):3439-3448. doi: 10.1021/acs.jmedchem.1c00029.
Francis S Willard 1,  David B Wainscott 1,  Aaron D Showalter 2,  Cynthia Stutsman 2,  Wenzhen Ma 2,  Guemalli R Cardona 1,  Richard W Zink 1,  Christopher M Corkins 1,  Qi Chen 1,  Nathan Yumibe 3,  Javier Agejas 4,  Graham R Cumming 4,  José Miguel Minguez 4,  Alma Jiménez 4,  Ana I Mateo 4,  Ana M Castaño 4,  Daniel A Briere 2,  Kyle W Sloop 2,  Ana B Bueno 4
Affiliations

Affiliations

  • 1 Discovery Chemistry Research and Technologies, Lilly Research Laboratories, Indianapolis, Indiana 46285, United States.
  • 2 Diabetes and Complications, Lilly Research Laboratories, Indianapolis, Indiana 46285, United States.
  • 3 Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, Indiana 46285, United States.
  • 4 Discovery Chemistry Research and Technologies, Lilly, S.A., Avda. de la Industria 30, Alcobendas, Madrid 28108, Spain.
PMID: 33721487 DOI: 10.1021/acs.jmedchem.1c00029
Abstract

The identification of LSN3318839, a positive allosteric modulator of the glucagon-like peptide-1 receptor (GLP-1R), is described. LSN3318839 increases the potency and efficacy of the weak metabolite GLP-1(9-36)NH2 to become a full agonist at the GLP-1R and modestly potentiates the activity of the highly potent full-length ligand, GLP-1(7-36)NH2. LSN3318839 preferentially enhances G protein-coupled signaling by the GLP-1R over β-arrestin recruitment. Ex vivo experiments show that the combination of GLP-1(9-36)NH2 and LSN3318839 produces glucose-dependent Insulin secretion similar to that of GLP-1(7-36)NH2. Under nutrient-stimulated conditions that release GLP-1, LSN3318839 demonstrates robust glucose lowering in animal models alone or in treatment combination with sitagliptin. From a therapeutic perspective, the biological properties of LSN3318839 support the concept that GLP-1R potentiation is sufficient for reducing hyperglycemia.

Figures
Products